Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
FDA is requesting additional information from Bristol-Myers Squibb on the company's BuSpar (buspirone) metabolite patent before permanently listing it in the "Orange Book."
FDA is requesting additional information from Bristol-Myers Squibb on the company's BuSpar (buspirone) metabolite patent before permanently listing it in the "Orange Book."